• 1. Cornell CC, Kittleson MD, Della Torre P, et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004;18:311321.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2. Fox P. Feline cardiomyopathies. In: Fox P, Sisson D, Moise N, eds. Textbook of canine and feline cardiology principles and clinical practice. 2nd ed. Philadelphia: Saunders-Elsevier, 1999;624641.

    • Search Google Scholar
    • Export Citation
  • 3. Patel MB, Loud AV, King BD, et al. Global myocardial hypertrophy in conscious dogs with chronic elevation of plasma norepinephrine levels. J Mol Cell Cardiol 1989;21(suppl 5):4961.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4. Claeys S, Rustichelli F, Noël S. Clinical evaluation of a single daily dose of phenylpropanolamine in the treatment of urethral sphincter mechanism incompetence in the bitch. Can Vet J 2011;52:501505.

    • Search Google Scholar
    • Export Citation
  • 5. Plumb DC. Phenylpropanolamine. In: Plumb's veterinary drug handbook. 7th ed. Stockholm, Wis: Pharma Vet Inc, 2008;726727.

  • 6. Crandell JM, Ware WA. Cardiac toxicity from phenylpropanolamine overdose in a dog. J Am Anim Hosp Assoc 2005;41:413420.

  • 7. Salerno SM, Jackson JL, Berbano EP. The impact of oral phenylpropanolamine on blood pressure: a meta-analysis and review of the literature. J Hum Hypertens 2005;19:643652.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8. Barst RJ, Abenhaim L. Fatal pulmonary arterial hypertension associated with phenylpropanolamine exposure. Heart 2004;90:e42.

  • 9. Thomas SH, Clark CK, Allen R, et al. A comparison of the cardiovascular effects of phenylpropanolamine and phenylephrine containing proprietary cold remedies. Br J Clin Pharmacol 1991;32:705711.

    • Search Google Scholar
    • Export Citation
  • 10. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000;343:18261832.

  • 11. Peterson KL, Lee JA, Hovda LR. Phenylpropanolamine toxicosis in dogs: 170 cases (2004–2009). J Am Vet Med Assoc 2011;239:14631469.

  • 12. Ginn JA, Bentley E, Stepien RL. Systemic hypertension and hypertensive retinopathy following PPA overdose in a dog. J Am Anim Hosp Assoc 2013;49:4653

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13. Long KM, Kirby R. An update on cardiovascular adrenergic receptor physiology and potential pharmacological applications in veterinary critical care. J Vet Emerg Crit Care 2008;18:225.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14. Woodcock EA, Du XJ, Reichelt ME, et al. Cardiac α-1 adrenergic drive in pathological remodeling. Cardiovasc Res 2008;77:452462.

  • 15. Vidal M, Wieland T, Lohse MJ, et al. β-Adrenergic receptor stimulation causes cardiac hypertrophy via Gβγ/ERK-dependent pathway. Cardiovasc Res 2012;96:255264.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16. King BD, Sack D, Kichuck M, et al. Absence of hypertension despite chronic marked elevations in plasma norepinephrine in conscious dogs. Hypertension 1987;9:582590.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17. Stewart JM, Patel MB, Wang J, et al. Chronic elevation of norepinephrine in conscious dogs produces hypertrophy with no loss of LV reserve. Am J Physiol 1992;262:H331H339

    • Search Google Scholar
    • Export Citation
  • 18. Laks MM, Morady F, Swan HJ. Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. Chest 1973;64:7578.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19. Osadchii OE. Cardiac hypertrophy induced by sustained β-adrenoreceptor activation: pathophysiological aspects. Heart Fail Rev 2007;12:6686.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20. Edmondson EF, Bright JM, Halsey CH, et al. Pathologic and cardiovascular characterization of pheochromocytoma-associated cardiomyopathy in dogs. Vet Pathol 2015;52:338343.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21. Vick J, Weiss L, Ellis S. Cardiovascular studies of phenylpropanolamine. Arch Int Pharmacodyn Ther 1994;327:1324.

  • 22. Carofiglio F, Hamaide AJ, Farnir F, et al. Evaluation of the urodynamic and hemodynamic effects of orally administered phenylpropanolamine and ephedrine in female dogs. Am J Vet Res 2006;67:723730.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23. Atkins C. Cardiac manifestations of systemic and metabolic disease. In: Fox P, Sisson D, Moise N, eds. Textbook of canine and feline cardiology principles and clinical practice. 2nd ed. Philadelphia: Saunders-Elsevier, 1999;757759.

    • Search Google Scholar
    • Export Citation
  • 24. Misbach C, Gouni V, Tissier RI. Echocardiographic and tissue Doppler imaging alterations associated with spontaneous canine systemic hypertension. J Vet Intern Med 2011;25:10251035.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25. Stepien RL. Pathophysiology of systemic hypertension and blood pressure assessment. In: Ettinger SG, Feldman EC, eds. Textbook of veterinary internal medicine. 7th ed. St Louis: Saunders-Elsevier, 2010;577582.

    • Search Google Scholar
    • Export Citation
  • 26. Panteleo V, Francey T, Fischer JR, et al. Application of hemodialysis for the management of acute uremia in cats: 119 cases (1993–2003). J Vet Intern Med 2004;18:418.

    • Search Google Scholar
    • Export Citation
  • 27. Plumb DC. Ephedrine. In: Plumb's veterinary drug handbook. 7th ed. Stockholm, Wis: Pharma Vet Inc, 2008;510512.

  • 28. Adamson PB, Suarez J, Ellis E, et al. Ephedrine increases ventricular arrhythmias in conscious dogs after myocardial infarction. J Am Coll Cardiol 2004;44:16751678.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29. Plumb DC. Ketamine. In: Plumb's veterinary drug handbook. 7th ed. Stockholm, Wis: Pharma Vet Inc, 2008;762768.

Advertisement

Myocardial hypertrophy associated with long-term phenylpropanolamine use in a dog

Kayla R. HansonDepartment of Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011.

Search for other papers by Kayla R. Hanson in
Current site
Google Scholar
PubMed
Close
 DVM
and
Wendy A. WareDepartment of Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011.

Search for other papers by Wendy A. Ware in
Current site
Google Scholar
PubMed
Close
 DVM
View More View Less

Abstract

CASE DESCRIPTION A 9-year-old spayed female Dalmatian was examined because of progressive pelvic limb paraparesis.

CLINICAL FINDINGS The dog had a history of chronic urinary incontinence and had been treated with phenylpropanolamine (PPA) for almost 8.5 years. Intervertebral disk disease at T12–13 was diagnosed, and a hemilaminectomy was performed. Three days after surgery, the dog developed a ventricular tachyarrhythmia. Severe left and mild right ventricular hypertrophy were detected by echocardiography.

TREATMENT AND OUTCOME The arrhythmia was controlled with sotalol. Phenylpropanolamine administration was discontinued immediately before surgery and was not resumed. Heart rate and rhythm and blood pressure were within reference limits, and the ventricular hypertrophy had almost completely resolved 5 months later. Sotalol administration was discontinued. Shortly after the 5-month recheck evaluation, PPA administration was resumed, albeit at a lower dosage than that before surgery, for control of urinary incontinence. At the 10-month recheck evaluation, the dog was hypertensive and ventricular hypertrophy had recurred. Discontinuation of PPA administration was recommended but not heeded. The dog developed marked azotemia 1.5 years after surgery, which was managed by the referring veterinarian, and was subsequently lost to follow-up.

CLINICAL RELEVANCE The fact that the ventricular hypertrophy almost completely resolved when PPA administration was discontinued and then recurred after it was resumed strongly suggested the drug was an important contributing factor to the cardiac disease of this patient. Patients receiving PPA on a long-term basis should be frequently monitored for cardiac disease, and use of other adrenergic receptor agonists should be avoided in such patients.

Abstract

CASE DESCRIPTION A 9-year-old spayed female Dalmatian was examined because of progressive pelvic limb paraparesis.

CLINICAL FINDINGS The dog had a history of chronic urinary incontinence and had been treated with phenylpropanolamine (PPA) for almost 8.5 years. Intervertebral disk disease at T12–13 was diagnosed, and a hemilaminectomy was performed. Three days after surgery, the dog developed a ventricular tachyarrhythmia. Severe left and mild right ventricular hypertrophy were detected by echocardiography.

TREATMENT AND OUTCOME The arrhythmia was controlled with sotalol. Phenylpropanolamine administration was discontinued immediately before surgery and was not resumed. Heart rate and rhythm and blood pressure were within reference limits, and the ventricular hypertrophy had almost completely resolved 5 months later. Sotalol administration was discontinued. Shortly after the 5-month recheck evaluation, PPA administration was resumed, albeit at a lower dosage than that before surgery, for control of urinary incontinence. At the 10-month recheck evaluation, the dog was hypertensive and ventricular hypertrophy had recurred. Discontinuation of PPA administration was recommended but not heeded. The dog developed marked azotemia 1.5 years after surgery, which was managed by the referring veterinarian, and was subsequently lost to follow-up.

CLINICAL RELEVANCE The fact that the ventricular hypertrophy almost completely resolved when PPA administration was discontinued and then recurred after it was resumed strongly suggested the drug was an important contributing factor to the cardiac disease of this patient. Patients receiving PPA on a long-term basis should be frequently monitored for cardiac disease, and use of other adrenergic receptor agonists should be avoided in such patients.

Contributor Notes

Dr. Hanson's present address is Lakeshore Veterinary Specialists, 2400 W Ryan Rd, Oak Creek, WI 53154.

Address correspondence to Dr. Hanson (khanson@lakeshorevetspecialists.com).